Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Joen, Chiang"'
Publikováno v:
Clinical Therapeutics. 36:588-592
Background Most previous studies of the incidence and economic impact of drug-related hospital admissions were not cancer specific, despite the fact that drug-related problems (DRPs) are of particular concern in oncology. Objective The goals of this
Publikováno v:
Journal of Oncology Pharmacy Practice. 21:93-101
Objectives To evaluate the clinical significance of interventions made by pharmacists in an oncology pharmacy in Singapore and their acceptance rate and to identify common drug-related problems and workflow-related interventions. Methods A two-month
Publikováno v:
Supportive Care in Cancer. 21:2137-2143
This study evaluated the prevalence, impact and predictive factors for the occurrence of febrile neutropenia (FN) in elderly patients receiving adjuvant myelosuppressive chemotherapy despite primary prophylaxis with G-CSF (breakthrough FN).This was a
Autor:
Lita Chew, Kevin Tay, Joen Chiang, Soon Thye Lim, Richard Quek, Vivianne Shih, Miriam Tao, Alexandre Chan
Publikováno v:
Journal of Oncology Pharmacy Practice. 19:24-30
At the National Cancer Centre Singapore, which is currently the largest ambulatory cancer centre in Singapore, clinical pharmacists have taken upon responsibilities to provide direct pharmaceutical care in the center’s lymphoma team since 2006. Giv
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 7:351-356
Aim: Recently, a number of studies have demonstrated the effectiveness of a single reduced dose of rasburicase for the management of tumor lysis syndrome (TLS) in adults. Whether Asian lymphoma patients similarly respond to a single dose of rasburica
Publikováno v:
Supportive Care in Cancer. 20:1525-1532
The aim of this study was to investigate the incidence of febrile neutropenia (FN) with adjuvant AC (doxorubicin and cyclophosphamide) chemotherapy among Asian early-stage breast cancer (ESBC) patients, to evaluate the impact of FN on chemotherapy de
Publikováno v:
International Journal of Hematology. 91:826-830
Rituximab (Mabthera®) is currently approved for the treatment of multiple subtypes of CD20-expressing, B-cell, non-Hodgkin’s lymphoma. This study aimed to investigate whether rapid infusion of rituximab over 90 min is feasible without compromising
Autor:
A, Chan, Alexandre, Chan, H L, Tan, Tay Hui, Lin, Vivianne, Shih, T H, Ching, Tan Huey, Ching, H C, Tan, Joen, Chiang
Publikováno v:
Alternative therapies in health and medicine. 18(1)
Over half of cancer patients in Singapore use some form of complementary or alternative medicine (CAM) to improve their immunity and general health status. The effectiveness of CAM, however, in reducing acute complications is currently unknown. Conce
Autor:
Joen, Chiang, Alexandre, Chan, Tracy, Lian, Kevin, Tay, Richard, Quek, Miriam, Tao, Soon Thye, Lim
Publikováno v:
Asia-Pacific journal of clinical oncology. 7(4)
Recently, a number of studies have demonstrated the effectiveness of a single reduced dose of rasburicase for the management of tumor lysis syndrome (TLS) in adults. Whether Asian lymphoma patients similarly respond to a single dose of rasburicase is
Publikováno v:
Journal of Clinical Oncology. 29:e489-e489